Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling

Zhu,Xiaofei; Han,Yue; Fang,Zhuyuan; Wu,Wenzhong; Ji,Mingde; Teng,Fengmeng; Zhu,Wei; Yang,Xuewen; Jia,Xuemei; Zhang,Chunbing

doi:10.3892/or.2013.2680

Progesterone protects ovarian cancer cells from cisplatin-induced inhibitory effects through progesterone receptor membrane component 1/2 as well as AKT signaling

Authors:
- Xiaofei Zhu
- Yue Han
- Zhuyuan Fang
- Wenzhong Wu
- Mingde Ji
- Fengmeng Teng
- Wei Zhu
- Xuewen Yang
- Xuemei Jia
- Chunbing Zhang
View Affiliations

Affiliations: Department of Laboratory Medicine, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of Gynecology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of Cardiology, Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: August 21, 2013 https://doi.org/10.3892/or.2013.2680
Pages: 2488-2494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Progesterone, also known as P4 (pregn-4-ene-3, 20-dione), is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species. Despite the physiological effects, P4 is also effective for the treatment of numerous pathological states, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus as well as cancer. Considering the hormone microenvironment of gynecological cancers, P4 should be particularly noted in ovarian cancer. The present study demonstrated that P4 protected the ovarian cancer cell line HO-8910 from cisplatin (CDDP)-induced cell cycle arrest and restored the cell migratory capability following treatment of CDDP. Mechanistically, both progesterone receptor membrane component 1 (PGRMC1) and the progesterone receptor (PGR) were decreased in the cells treated with CDDP plus P4, while the level of progesterone receptor membrane component 2 (PGRMC2) was significantly elevated. Reversely, in the HO-8910 cells treated with CDDP alone, levels of both PGRMC1 and PGR were increased while the level of PGRMC2 was decreased. In addition to the receptor expression profile, the PI3K/AKT signaling pathway was also involved in the action of P4 in the CDDP-resistant HO-8910 cells, and a chemical inhibitor for PI3K, LY294002, significantly abolished the anti-apoptotic effect of P4. Consequently, the addition of a PI3K inhibitor to CDDP-based chemotherapy may have a more beneficial application for ovarian cancer therapy.

View Figures

View References

1	Salzberg M, Thurlimann B, Bonnefois H, et al: Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology. 68:293–298. 2005. View Article : Google Scholar : PubMed/NCBI
2	O’Brien ME, Dowsett M, Fryatt I and Wiltshaw E: Steroid hormone profile in postmenopausal women with ovarian cancer. Eur J Cancer. 30A:442–445. 1994.PubMed/NCBI
3	Halperin R, Hadas E, Langer R, Bukovsky I and Schneider D: Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. Int J Gynecol Cancer. 9:502–507. 1999. View Article : Google Scholar : PubMed/NCBI
4	Modugno F, Ness RB and Cottreau CM: Cigarette smoking and the risk of mucinous and nonmucinous epithelial ovarian cancer. Epidemiology. 13:467–471. 2002. View Article : Google Scholar : PubMed/NCBI
5	Franks AL, Lee NC, Kendrick JS, Rubin GL and Layde PM: Cigarette smoking and the risk of epithelial ovarian cancer. Am J Epidemiol. 126:112–117. 1987.PubMed/NCBI
6	Green A, Purdie D, Bain C, Siskind V and Webb PM: Cigarette smoking and risk of epithelial ovarian cancer (Australia). Cancer Causes Control. 12:713–719. 2001. View Article : Google Scholar : PubMed/NCBI
7	Liu L, Wang J, Zhao L, et al: Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology. 150:3186–3196. 2009. View Article : Google Scholar
8	Chen X, Cheng L, Jia X, et al: Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice. Neoplasia. 11:1272–1284. 2009.
9	Tang Q, Qin D, Lv Z, et al: Herpes simplex virus type 2 triggers reactivation of Kaposi’s sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat. PLoS One. 7:e316522012.PubMed/NCBI
10	Qin D, Feng N, Fan W, et al: Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol. 11:2402011.PubMed/NCBI
11	Albrecht C, Huck V, Wehling M and Wendler A: In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1. Steroids. 77:1543–1550. 2012. View Article : Google Scholar : PubMed/NCBI
12	Rodon J, Dienstmann R, Serra V and Tabernero J: Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 10:143–153. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wu J, Chen C and Zhao KN: Phosphatidylinositol 3-kinass signalings as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 13:143–156. 2013. View Article : Google Scholar : PubMed/NCBI
14	Polak R and Buitenhuis M: The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood. 119:911–923. 2012. View Article : Google Scholar : PubMed/NCBI
15	Sun CC, Ramirez PT and Bodurka DC: Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol. 4:18–29. 2007. View Article : Google Scholar : PubMed/NCBI
16	Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S and Tanwanich S: Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer. 19:620–627. 2009. View Article : Google Scholar : PubMed/NCBI
17	Shanmughapriya S, Senthilkumar G, Vinodhini K, Das BC, Vasanthi N and Natarajaseenivasan K: Viral and bacterial aetiologies of epithelial ovarian cancer. Eur J Clin Microbiol Infect Dis. 31:2311–2317. 2012. View Article : Google Scholar : PubMed/NCBI
18	Rosa MI, Silva GD, de Azedo Simoes PW, et al: The prevalence of human papillomavirus in ovarian cancer: a systematic review. Int J Gynecol Cancer. 23:437–441. 2013. View Article : Google Scholar : PubMed/NCBI
19	Gonzalez ER: Estrogen, progesterone receptors in ovarian cancer. JAMA. 245:16261981. View Article : Google Scholar : PubMed/NCBI
20	Yin G, Chen R, Alvero AB, et al: TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene. 29:3545–3553. 2010. View Article : Google Scholar : PubMed/NCBI
21	Maccio A, Madeddu C, Massa D, et al: Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 106:362–367. 2005. View Article : Google Scholar : PubMed/NCBI
22	Lee KB, Byun HJ, Park SH, Park CY, Lee SH and Rho SB: CYR61 controls p53 and NF-κB expression through PI3K/Akt/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett. 315:86–95. 2012.PubMed/NCBI
23	Murdoch WJ, Van Kirk EA, Isaak DD and Shen Y: Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol. 110:251–255. 2008. View Article : Google Scholar : PubMed/NCBI
24	Seeger H, Wallwiener D and Mueck AO: Is there a protective role of progestogens on the proliferation of human ovarian cancer cells in the presence of growth factors? Eur J Gynaecol Oncol. 27:139–141. 2006.PubMed/NCBI
25	Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol. 1:732003. View Article : Google Scholar : PubMed/NCBI
26	Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G and Darai E: Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep. 15:743–748. 2006.PubMed/NCBI
27	Syed V, Ulinski G, Mok SC, Yiu GK and Ho SM: Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res. 61:6768–6776. 2001.PubMed/NCBI
28	Peluso JJ, Gawkowska A, Liu X, Shioda T and Pru JK: Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology. 150:4846–4854. 2009. View Article : Google Scholar : PubMed/NCBI
29	Peluso JJ: Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids. 76:903–909. 2011.
30	Lenhard M, Tereza L, Heublein S, et al: Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer. 12:5532012. View Article : Google Scholar : PubMed/NCBI
31	Leite DB, Junqueira MG, de Carvalho CV, et al: Progesterone receptor (PROGINS) polymorphism and the risk of ovarian cancer. Steroids. 73:676–680. 2008. View Article : Google Scholar : PubMed/NCBI
32	Gabra H, Watson JE, Taylor KJ, et al: Definition and refinement of a region of loss of heterozygosity at 11q23.3–q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res. 56:950–954. 1996.
33	Petz LN, Nardulli AM, Kim J, Horwitz KB, Freedman LP and Shapiro DJ: DNA bending is induced by binding of the glucocorticoid receptor DNA binding domain and progesterone receptors to their response element. J Steroid Biochem Mol Biol. 60:31–41. 1997. View Article : Google Scholar : PubMed/NCBI
34	Noguchi T, Kitawaki J, Tamura T, et al: Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J Steroid Biochem Mol Biol. 44:657–660. 1993. View Article : Google Scholar : PubMed/NCBI
35	Mifsud W and Bateman A: Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain. Genome Biol. 3:Research00682002. View Article : Google Scholar : PubMed/NCBI
36	Szczesna-Skorupa E and Kemper B: Progesterone receptor membrane component 1 inhibits the activity of drug-metabolizing cytochromes P450 and binds to cytochrome P450 reductase. Mol Pharmacol. 79:340–350. 2011. View Article : Google Scholar : PubMed/NCBI
37	Oda S, Nakajima M, Toyoda Y, Fukami T and Yokoi T: Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. Drug Metab Dispos. 39:2057–2065. 2011. View Article : Google Scholar : PubMed/NCBI
38	Leake K, Singhal J, Nagaprashantha LD, Awasthi S and Singhal SS: RLIP76 regulates PI3K/Akt signaling and chemo-radiotherapy resistance in pancreatic cancer. PLoS One. 7:e345822012. View Article : Google Scholar : PubMed/NCBI
39	Kim TR, Cho EW, Paik SG and Kim IG: Hypoxia-induced SM22α in A549 cells activates the IGF1R/PI3K/Akt pathway, conferring cellular resistance against chemo- and radiation therapy. FEBS Lett. 586:303–309. 2012.